AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP

WASHINGTON--(BUSINESS WIRE)-- Yesterday, AIDS Healthcare Foundation sent a letter signed by over 80 organizations to Gilead Sciences denouncing the company’s plan for high-single digit price hikes for several of its HIV medications. The immediate effect of the price spike guarantees that AIDS Drug Assistance Programs (ADAPs), a lifeline for low-income patients, will furnish fewer prescriptions to those most in need. Unfortunately, the decision to make life-saving therapeutics more expensive is not a one-off but follows a pattern under the leadership of Gilead’s CEO, Daniel O’Day.

O’Day has ruthlessly sought to boost profits by restricting access to Gilead’s HIV medicines. From patent manipulation to curtailing patient assistance programs, O’Day has proven that drug giants do not need to innovate to make money. Under his tenure, Gilead has put up multiple roadblocks to make it harder for medically underserved Americans to attain their medications. O’Day has had one goal – maximizing profits of the older drugs in Gilead’s portfolio instead of investing in the breakthrough HIV therapeutics of the future.

AIDS Healthcare Foundation (AHF), the world’s largest HIV/AIDS healthcare organization, provides cutting-edge medicine and advocacy to more than 2.6 million individuals across 49 countries, including the U.S. and in Africa, Latin America/Caribbean, the Asia/Pacific Region, and Eastern Europe. To learn more about AHF, visit us online at AIDShealth.org, find us on Facebook, and follow us on Instagram, Twitter, and TikTok.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251021254615/en/

MEDIA CONTACTS:
John Hassell, AHF National Director of Advocacy
1.202.774.4854 mobile. [email protected]

Ged Kenslea, Sr. Director, Communications, AHF
1.323.791.5526 mobile [email protected]

Source: AIDS Healthcare Foundation

You May Also Be Interested In

• Korn Ferry Completes Acquisition of AMS
• Rimsys Announces AI-Native Market Access for Regulated Products
• Kura Oncology to Participate in Three Investor Conferences in September